Literature DB >> 35387873

Interleukin-33 Exacerbates IgA Glomerulonephritis in Transgenic Mice Overexpressing B Cell Activating Factor.

Yuan Min Wang1, Karli Shaw1, Geoff Yu Zhang1, Edmund Y M Chung1, Min Hu2, Qi Cao2, Yiping Wang2, Guoping Zheng2, Huiling Wu3,4, Steven J Chadban3,4, Hugh J McCarthy1, David C H Harris2, Fabienne Mackay5, Shane T Grey6, Stephen I Alexander7.   

Abstract

BACKGROUND: The cytokine IL-33 is an activator of innate lymphoid cells 2 (ILC2s) in innate immunity and allergic inflammation. B cell activating factor (BAFF) plays a central role in B cell proliferation and differentiation, and high levels of this protein cause excess antibody production, including IgA. BAFF-transgenic mice overexpress BAFF and spontaneously develop glomerulonephritis that resembles human IgA nephropathy.
METHODS: We administered IL-33 or PBS to wild-type and BAFF-transgenic mice. After treating Rag1-deficient mice with IL-33, with or without anti-CD90.2 to preferentially deplete ILC2s, we isolated splenocytes, which were adoptively transferred into BAFF-transgenic mice.
RESULTS: BAFF-transgenic mice treated with IL-33 developed more severe kidney dysfunction and proteinuria, glomerular sclerosis, tubulointerstitial damage, and glomerular deposition of IgA and C3. Compared with wild-type mice, BAFF-transgenic mice exhibited increases of CD19+ B cells in spleen and kidney and ILC2s in kidney and intestine, which were further increased by administration of IL-33. Administering IL-33 to wild-type mice had no effect on kidney function or histology, nor did it alter the number of ILC2s in spleen, kidney, or intestine. To understand the role of ILC2s, splenocytes were transferred from IL-33-treated Rag1-deficient mice into BAFF-transgenic mice. Glomerulonephritis and IgA deposition were exacerbated by transfer of IL-33-stimulated Rag1-deficient splenocytes, but not by ILC2 (anti-CD90.2)-depleted splenocytes. Wild-type mice infused with IL-33-treated Rag1-deficient splenocytes showed no change in kidney function or ILC2 numbers or distribution.
CONCLUSIONS: IL-33-expanded ILC2s exacerbated IgA glomerulonephritis in a mouse model. These findings indicate that IL-33 and ILC2s warrant evaluation as possible mediators of human IgA nephropathy.
Copyright © 2022 by the American Society of Nephrology.

Entities:  

Keywords:  B cell activating factor; IL-33; IgA glomerulonephritis; innate lymphoid cells 2; mice; suppression of tumorigenicity 2 (ST2); transgenic

Mesh:

Substances:

Year:  2022        PMID: 35387873      PMCID: PMC9063894          DOI: 10.1681/ASN.2021081145

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   14.978


  79 in total

1.  Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy.

Authors:  Douglas D McCarthy; Julie Kujawa; Cheryl Wilson; Adrian Papandile; Urjana Poreci; Elisa A Porfilio; Lesley Ward; Melissa A E Lawson; Andrew J Macpherson; Kathy D McCoy; York Pei; Lea Novak; Jeannette Y Lee; Bruce A Julian; Jan Novak; Ann Ranger; Jennifer L Gommerman; Jeffrey L Browning
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

2.  ILC2: There's a New Cell in Town.

Authors:  Yuan Min Wang; Mahnoor Bakhtiar; Stephen I Alexander
Journal:  J Am Soc Nephrol       Date:  2017-05-31       Impact factor: 10.121

3.  Potentiating Tissue-Resident Type 2 Innate Lymphoid Cells by IL-33 to Prevent Renal Ischemia-Reperfusion Injury.

Authors:  Qi Cao; Yiping Wang; Zhiguo Niu; Chengshi Wang; Ruifeng Wang; Zhiqiang Zhang; Titi Chen; Xin Maggie Wang; Qing Li; Vincent W S Lee; Qingsong Huang; Jing Tan; Minghao Guo; Yuan Min Wang; Guoping Zheng; Di Yu; Stephen I Alexander; Hui Wang; David C H Harris
Journal:  J Am Soc Nephrol       Date:  2018-01-02       Impact factor: 10.121

4.  Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.

Authors:  Bengt C Fellström; Jonathan Barratt; Heather Cook; Rosanna Coppo; John Feehally; Johan W de Fijter; Jürgen Floege; Gerd Hetzel; Alan G Jardine; Francesco Locatelli; Bart D Maes; Alex Mercer; Fernanda Ortiz; Manuel Praga; Søren S Sørensen; Vladimir Tesar; Lucia Del Vecchio
Journal:  Lancet       Date:  2017-03-28       Impact factor: 79.321

Review 5.  Interleukin 33 is a guardian of barriers and a local alarmin.

Authors:  Nikolas T Martin; Michael U Martin
Journal:  Nat Immunol       Date:  2016-02       Impact factor: 25.606

6.  The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults.

Authors:  Rosanna Coppo; Stéphan Troyanov; Roberta Camilla; Ronald J Hogg; Daniel C Cattran; H Terence Cook; John Feehally; Ian S D Roberts; Alessandro Amore; Charles E Alpers; Jonathan Barratt; Francois Berthoux; Stephen Bonsib; Jan A Bruijn; Vivette D'Agati; Giuseppe D'Amico; Steven N Emancipator; Francesco Emma; Franco Ferrario; Fernando C Fervenza; Sandrine Florquin; Agnes B Fogo; Colin C Geddes; Hermann J Groene; Mark Haas; Andrew M Herzenberg; Prue A Hill; Stephen I Hsu; J Charles Jennette; Kensuke Joh; Bruce A Julian; Tetsuya Kawamura; Fernand M Lai; Lei S Li; Philip K Li; Zhi H Liu; Sergio Mezzano; F Paolo Schena; Yasuhiko Tomino; Patrick D Walker; Haiyan Wang; Jan J Weening; Norishige Yoshikawa; Hong Zhang
Journal:  Kidney Int       Date:  2010-03-03       Impact factor: 10.612

7.  T cell-derived IFN-γ downregulates protective group 2 innate lymphoid cells in murine lupus erythematosus.

Authors:  Mathis Düster; Martina Becker; Ann-Christin Gnirck; Malte Wunderlich; Ulf Panzer; Jan-Eric Turner
Journal:  Eur J Immunol       Date:  2018-05-17       Impact factor: 5.532

8.  Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.

Authors:  Richard Furie; Brad H Rovin; Frédéric Houssiau; Ana Malvar; Y K Onno Teng; Gabriel Contreras; Zahir Amoura; Xueqing Yu; Chi-Chiu Mok; Mittermayer B Santiago; Amit Saxena; Yulia Green; Beulah Ji; Christi Kleoudis; Susan W Burriss; Carly Barnett; David A Roth
Journal:  N Engl J Med       Date:  2020-09-17       Impact factor: 91.245

9.  Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN).

Authors:  Maria De Angelis; Eustacchio Montemurno; Maria Piccolo; Lucia Vannini; Gabriella Lauriero; Valentina Maranzano; Giorgia Gozzi; Diana Serrazanetti; Giuseppe Dalfino; Marco Gobbetti; Loreto Gesualdo
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

10.  A Novel Hybrid Cytokine IL233 Mediates regeneration following Doxorubicin-Induced Nephrotoxic Injury.

Authors:  Vikram Sabapathy; Nardos Tesfaye Cheru; Rebecca Corey; Saleh Mohammad; Rahul Sharma
Journal:  Sci Rep       Date:  2019-03-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.